Artiva Biotherapeutics (ARTV) vs Zura Bio (ZURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Artiva Biotherapeutics (ARTV) has outperformed Zura Bio (ZURA) over the past year, gaining 131.3% versus a loss of 11.3%. Zura Bio is the larger company by market cap ($383.3 million vs $339.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARTV | ZURA |
|---|---|---|
| Share price | $6.94 | $4.00 |
| Market cap | $339.30M | $383.32M |
| 1-day change | +2.06% | -3.15% |
| YTD return | +61.77% | -23.66% |
| 1-year return | +131.33% | -11.31% |
| EPS (TTM) | $-3.23 | $-1.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.53 | $7.44 |
| 52-week low | $2.71 | $3.15 |
| Distance from 52-week high | -52.24% | -46.24% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +415.85% | +350.00% |
| Average volume | 400.97K | 1.44M |
| Shares outstanding | 48.89M | 95.83M |
| Employees | 115 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARTV has outperformed ZURA by 142.6 percentage points over the past year.
About Artiva Biotherapeutics
ARTV stock →Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 115 employees
About Zura Bio
ZURA stock →Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 40 employees
ARTV vs ZURA FAQ
Which is bigger, Artiva Biotherapeutics or Zura Bio?
Zura Bio (ZURA) is larger, with a market capitalization of $383.32M compared with $339.30M for Artiva Biotherapeutics (ARTV).
Which stock has performed better over the past year, ARTV or ZURA?
ARTV returned +131.33% over the past 12 months, compared with -11.31% for ZURA (price return, excluding dividends). Past performance does not predict future results.
Are Artiva Biotherapeutics and Zura Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.